General Information
Revision date
2021-01-27
Product name
TYDEMYTM (drospirenone, ethinyl estradiol and levomefolate calcium tablets and levomefolate calcium tablets)
Manufacturer Name
Lupin Limited
Icons in SDS
Company Information
company name
Lupin Limited
Section 2
SECTION 2: Hazards identification
Fire and Explosion Expected to be non-combustible. Health Do not prescribe Tydemy to women who are known to have the following: Renal impairment Adrenal insufficiency A high risk of arterial or venous thrombotic diseases. Examples include women who are known to: о Smoke, if over age 35 о Have deep vein thrombosis or pulmonary embolism, now or in the past о Have cerebrovascular disease о Have coronary artery disease о Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) о Have inherited or acquired hypercoagulopathies о Have uncontrolled hypertension о Have diabetes mellitus with vascular disease о Have headaches with focal neurological symptoms or have migraine headaches with or without aura if over age 35 Undiagnosed abnormal uterine bleeding Breast cancer or other estrogen- or progestin-sensitive cancer, now or in the past Liver tumor (benign or malignant) or liver disease Pregnancy, because there is no reason to use COCs during pregnancy Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir due to the potential for ALT elevations
Environmental hazards
No information is available about the potential of this product to produce adverse environmental effects.